Compare UK prices. 40+ products · 17 retailers scored
PeptideClear UK

Encyclopedia entry

Sarcopenia and GLP-1

Sarcopenia is the age-related loss of skeletal muscle mass and strength, accelerating after age 50. Rapid weight loss on GLP-1 medications inevitably includes some lean mass alongside fat loss. The combined effect (existing age-related decline plus medication-accelerated loss) is why muscle preservation strategies are particularly relevant for older GLP-1 users.

What sarcopenia is

Skeletal muscle mass peaks around age 30 to 35 and declines by approximately 0.5 to 1 percent per year thereafter, accelerating after 65. Loss of strength typically outpaces loss of mass. Functional consequences (falls, frailty, reduced metabolic rate, insulin resistance) drive much of the health burden of ageing.

Lean mass loss on GLP-1

Published estimates from SURMOUNT and STEP secondary endpoints suggest 25 to 40 percent of total weight loss on GLP-1 is lean mass when no specific muscle preservation strategy is in place. With high protein intake (1.2 to 1.6 g/kg/day) plus resistance training, the lean-mass fraction of total loss can be reduced significantly. The proportion is the same across age groups; the absolute impact is more consequential for older users with less reserve.

What preservation strategies look like

Your prescriber and dietitian adjust strategies for your circumstances. We do not provide specific exercise prescriptions to specific people.

Why this matters for the GLP-1 lifecycle

Maintained muscle mass at goal weight predicts both metabolic resilience (insulin sensitivity, resting metabolic rate) and weight-regain resistance after discontinuation. The aftercare and maintenance phase depends partly on the body composition that emerged from the loss phase.

Related: protein on GLP-1 · muscle preservation · body recomp hub.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-18